-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

731.O1.6 731. Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis Clinically Relevant Abstract

Symposia: Autologous Transplantation: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, Acute Myeloid Malignancies, AML, adult, autoimmune disorders, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Clinical Practice (Health Services and Quality), Non-Biological therapies, epidemiology, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Chemotherapy, Combination therapy, health outcomes research, T Cell lymphoma, pediatric, Checkpoint Inhibitor, Diseases, Immune Disorders, patient-reported outcomes, real-world evidence, Therapies, clinical procedures, registries, Lymphoid Malignancies, young adult , Adverse Events, survivorship, Myeloid Malignancies, Technology and Procedures, Study Population, Human, Transplantation
Sunday, December 11, 2022: 9:30 AM-11:00 AM
220-222 (Ernest N. Morial Convention Center)
Moderators:
Joanna Zurko, MD, University of Wisconsin and Zohra Nooruddin, MD, Long School of Medicine, University of Texas Health San Antonio
Disclosures:
Nooruddin: Astrazeneca: Research Funding.
9:30 AM

Juan Carlos Olivares-Gazca, MD1,2*, Daniela Sánchez-Bonilla, MD1,2*, José Antonio Fernández-Gutiérrez, MD1,2*, Oscar A. Reyes-Cisneros, MD3*, Moisés Manuel Gallardo-Pérez, MD1,2*, Guillermo José Ruiz-Delgado, MD, FACP1* and Guillermo José Ruiz-Argüelles, MD, FRCP (Glasg), MACP, DSc(hc), FRCP4

1Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico
2Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico
3Universidad Anáhuac Puebla, Puebla, Mexico
4Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, PU, Mexico

9:45 AM

Felix Keil1*, Antonia Maria Susanne Müller2,3*, Andrea Berghold, Univ.Prof. DI Dr.4*, Veronika Buxhofer-Ausch, MD5*, Judith Schuster, Mag. Dr.6*, Regina Riedl, DI Dr.4*, Corinne Vorburger7*, Alexandra Boehm, MD8*, Michael Panny, MD8*, Thomas Noesslinger, MD8*, Richard Greil, MD6,9,10, Panagiotis Samaras, MD11* and Thomas Pabst, MD12

13rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Vienna, Austria
2Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
3Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
4Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
5Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
6Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Salzburg, Austria
7Department of Medical Oncology, University Hospital Bern, Inselspital, Bern, Switzerland
83rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
9Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Salzburg, Austria
10Paracelsus Medical University, Salzburg, Austria
11Clinic for Hematology & Oncology Hirslanden Zurich, Zürich, Switzerland
12University Hospital Bern, Inselspital, Bern, Switzerland

10:00 AM

Yago Nieto, MD1, Benigno C Valdez, PhD1, Peter F Thall, PhD2*, Jeremy L. Ramdial, MD1, Samer A Srour, MD, MS1, Chitra Hosing, MD1, Neeraj Saini, MD1, Amin M Alousi, MD1, Muzaffar H Qazilbash, MD1, Uday R Popat, MD1, Alison Gulbis, PharmD3*, Terri Lynn Shigle, PharmD3*, Roland Bassett, MS2*, Maria Guillermo-Pacheco1*, Celina Ledesma1*, Paolo Strati, MD4, Sairah Ahmed, MD4, Raphael Steiner, MD4*, Jason Westin, MD4, Ranjit Nair, MD4*, Swaminathan P. Iyer, MD4, Richard E Champlin, MD1, Elizabeth J Shpall, MD1 and Borje S Andersson, MD, PhD1

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
3Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

10:15 AM

Mwanasha H. Merrill, MD1, Parastoo B. Dahi, MD2, Robert A. Redd, MS3*, Mikaela M. McDonough, BS4*, Yi-Bin Chen, MD, MS5, Ann S. LaCasce, MD6, David C. Fisher, MD4*, Alex F. Herrera, MD7, Caron A. Jacobson, MD8, Austin I. Kim, MD4, Reid W. Merryman, MD9, Oreofe O. Odejide, MD, MPH10, Samuel Ng, MD, PhD4*, Yago Nieto, MD11, Craig S. Sauter, MD12*, Gunjan L. Shah, MD13*, Jasmine Zain, MD14, Philippe Armand, MD, PhD4* and Eric D Jacobsen8

1Dana Farber Cancer Institute, boston, MA
2Memorial Sloan Kettering Cancer Center, New York, NY
3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
5Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA
6Division of Hematologic Malignancies, Dana-Farber Cancer Inst., Boston, MA
7City of Hope, Duarte, CA
8Dana-Farber Cancer Institute, Boston, MA
9Brigham and Women's Hospital, Boston, MA
10Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
11Department of Stem Cell Transplantation and Cellular Therapy, UT M.D. Anderson Cancer Ctr., Houston, TX
12Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland, OH
13Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
14City of Hope Comprehensive Cancer Center, Duarte, CA

10:30 AM

Scott R. Solomon, MD1, Melhem Solh, MD1, Lawrence E. Morris Jr., MD1*, H. Kent Holland, MD1, Lizamarie Bachier-Rodriguez, MD1*, Xu Zhang, PhD2*, Caitlin Guzowski1*, Katelin C Jackson1*, Stacey Brown, CCRP1* and Asad Bashey, MD, PhD1

1Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA
2Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

10:45 AM

Anna Sallfors Holmqvist, MD, PhD1*, Qingrui Meng, MS2*, Chen Dai, MS3*, Lindsey Hageman, MPH2*, Wendy Landier, PhD, CRNP2*, Jessica Wu, MPH2*, Liton F. Francisco, BS2*, Elizabeth Schlichting, MBA2*, Nora Balas, MSPH2*, Alysia Bosworth, BA4*, Hok Sreng Te5*, Ravi Bhatia, MD6, Joseph Rosenthal, MD7*, Lennie Wong, PhD8*, Daniel J. Weisdorf, MD9, Saro H. Armenian, DO, MPH10 and Smita Bhatia, MD, MPH2

1Department of Clinical Sciences, Lund University, Pediatric Oncology and Hematology, Skane University Hospital, Lund, Sweden
2Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
3Institute for Cancer outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
4Department of Population Sciences, City of Hope, Durate, CA
5University of Minnesota, Minneapolis, MN
6Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
7Pediatric Hematology/Oncology, City of Hope, Duarte, CA
8Department of Population Sciences, City of Hope, Duarte, CA
9Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN
10Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, CA

*signifies non-member of ASH